From directing Sun-Ranbaxy to divest certain products back in 2015 to recently ordering behavioural remedies in L&T-Schneider deal, the Competition Commission of India’s approach in Phase II investigations has come a long way. If the regulator believes that on the face of it, a deal is likely to cause appreciable adverse effects on competition, it conducts a detailed investigation into the transaction. This, in competition law parlan...